ストックスクリーナーアプリを入手
0.851
0.56%
-0.0048
前日終値:
$0.8558
開ける：
$0.85
24時間の取引高:
96,209
Relative Volume:
0.33
時価総額：
$7.00M
収益：
-
当期純損益:
$-39.14M
株価収益率:
-0.1425
EPS:
-5.97
ネットキャッシュフロー:
$-28.20M
1週間 パフォーマンス:
+25.15%
1か月 パフォーマンス:
+16.98%
6か月 パフォーマンス:
-75.82%
1年 パフォーマンス:
-94.61%
1日の値動き範囲:
$0.8101
$0.867
1週間の範囲:
$0.6802
$0.945
52週間の値動き範囲:
$0.65
$26.25
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
名前
Citius Pharmaceuticals Inc
セクター
電話
(908) 967-6676
住所
11 COMMERCE DRIVE, CRANFORD, NJ
CTXR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.851 | 7.00M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | アップグレード | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 開始されました | Maxim Group | Buy |
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
Northern Trust Corp Sells 306,583 Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - mx.advfn.com
Citius Pharmaceuticals Issues $1M Promissory Note to Pagoda - TipRanks
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives $54.50 Consensus Price Target from Brokerages - Defense World
Why Shares of SoundHound AI Are Soaring Today - The Globe and Mail
Citius Pharmaceuticals (NASDAQ:CTXR) Cut to Hold at Maxim Group - Defense World
Maxim Group Downgrades Citius Pharmaceuticals (CTXR) - MSN
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Citius Pharmaceuticals (CTXR) Downgraded to Hold by Maxim Group - GuruFocus
Maxim Downgrades Citius Oncology to Hold From Buy - marketscreener.com
Citius Pharmaceuticals (CTXR) Downgraded to Hold by Maxim | CTXR Stock News - GuruFocus
Citius Pharmaceuticals (NASDAQ:CTXR) Earns Buy Rating from D. Boral Capital - Defense World
Citius Pharmaceuticals (CTXR) Receives Continued "Buy" Rating fr - GuruFocus
Citius Pharmaceuticals Reports Q1 2025 Earnings and Strategic Developments - TipRanks
Citius Pharmaceuticals (CTXR) Receives Continued "Buy" Rating from Analyst | CTXR Stock News - GuruFocus
Citius Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financi - GuruFocus
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 - GuruFocus
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Laun - GuruFocus
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Launch | CTXR Stock News - GuruFocus
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Pharmaceuticals Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Pharmaceuticals (CTXR) to Release Quarterly Earnings on Tuesday - Defense World
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™ - Barchart.com
Citius Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - The Malaysian Reserve
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | CTXR Stock News - GuruFocus
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Shares Sold by Geode Capital Management LLC - Defense World
3 Value Stocks with Mounting Challenges - The Globe and Mail
Citius Pharmaceuticals stock hits 52-week low at $0.92 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $0.92 By Investing.com - Investing.com Canada
Citius Pharmaceuticals (CTXR) Price Target Adjusted to $4 Amid S - GuruFocus
Citius Pharmaceuticals stock hits 52-week low at $0.94 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals stock hits 52-week low at $0.94 - Investing.com Australia
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Longview News-Journal
Why Lululemon (LULU) Shares Are Getting Obliterated Today - The Globe and Mail
Citius Pharmaceuticals stock plummets on $2M registered direct offering of common stock - MSN
Citius Pharmaceuticals stock hits 52-week low at $1.21 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $1.21 By Investing.com - Investing.com India
Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharma secures $2 million in stock offering - Investing.com Australia
Citius Pharmaceuticals announces $2M registered direct offering of common stock - TipRanks
CTXR’s Stock Woes: Down -87.99% in 6 Months, Down -87.99% in Just 5 Days - investchronicle.com
IL-2s gain ground as US market heads for $4 billion by 2034 - The Pharma Letter
Analysts Expect Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) To Breakeven Soon - simplywall.st
Citius Pharmaceuticals Inc (CTXR) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):